Key Insights

Highlights

Success Rate

80% trial completion

Published Results

13 trials with published results (22%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

8.3%

5 terminated out of 60 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

30%

18 trials in Phase 3/4

Results Transparency

65%

13 of 20 completed with results

Key Signals

13 with results80% success

Data Visualizations

Phase Distribution

38Total
Not Applicable (4)
P 1 (10)
P 2 (6)
P 3 (17)
P 4 (1)

Trial Status

Completed20
Recruiting12
Unknown9
Active Not Recruiting6
Terminated5
Withdrawn5

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (60)

Showing 20 of 20 trials
NCT05560282Phase 3TerminatedPrimary

Fenfluramine for Adult Dravet Patients

NCT07531745Phase 1RecruitingPrimary

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

NCT05044819Phase 4Active Not Recruiting

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

NCT04437004UnknownPrimary

Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)

NCT05419492Phase 1RecruitingPrimary

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

NCT06660394Phase 3RecruitingPrimary

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06872125Phase 3RecruitingPrimary

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT07013331Not ApplicableNot Yet Recruiting

A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome

NCT05126914Recruiting

Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents

NCT06118255Phase 3Active Not RecruitingPrimary

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

NCT05485831Recruiting

Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY

NCT04740476Phase 2Active Not RecruitingPrimary

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

NCT07251673RecruitingPrimary

Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

NCT01983722UnknownPrimary

Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome

NCT05472389Not ApplicableActive Not RecruitingPrimary

Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome

NCT06283212Phase 1Active Not RecruitingPrimary

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

NCT05626634Phase 2Completed

Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

NCT03936777Phase 3CompletedPrimary

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

NCT06112275Phase 1Active Not RecruitingPrimary

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

NCT07176832Phase 1CompletedPrimary

Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)

Scroll to load more

Research Network

Activity Timeline